Search

Displaying results 4941 - 4950 of 8974 in total
  1. Drug

    Triazavirin

    go.drugbank.com/drugs/DB15622
    Investigational

    [L12087] Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.[A191625]

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    It is currently marketed in Canada by Valeant under the tradename Cophylac.

  3. Drug

    Cefradine

    go.drugbank.com/drugs/DB01333
    ApprovedWithdrawn

    A semi-synthetic cephalosporin antibiotic.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    AG-858

    go.drugbank.com/drugs/DB05502
    Investigational

    HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. … Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.

  5. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    [A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]

  6. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.

  8. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. … It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.